Clinicopathologic Features and Germline Sequence Variants in Young Patients (≤40 Years Old) with Pancreatic Ductal Adenocarcinoma

Pancreas

Volumn 45, Issue 7, 2016, Pages 1056-1061

  Ohmoto, Akihiro ^a   Yachida, Shinichi ^a   Kubo, Emi ^b   Takai, Erina ^a   Suzuki, Masami ^a   Shimada, Kazuaki ^b   Okusaka, Takuji ^b   Morizane, Chigusa ^b  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

early onset cancer; familial pancreatic cancer; germline variants; massive parallel sequencing; pancreatic ductal adenocarcinoma

Indexed keywords

DNA;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; FAMILIAL CANCER; FAMILY HISTORY; FEMALE; FIRST DEGREE RELATIVE; GENE SEQUENCE; GENETIC BACKGROUND; GENETIC PREDISPOSITION; GERMLINE MUTATION; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MIDDLE AGED; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SURVIVAL RATE; SURVIVAL TIME; VERY ELDERLY; YOUNG ADULT; DNA SEQUENCE; GENETICS; METABOLISM; PANCREAS; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; PROCEDURES;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PANCREATIC DUCTAL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; MALE; MIDDLE AGED; PANCREAS; PANCREATIC NEOPLASMS; SEQUENCE ANALYSIS, DNA; YOUNG ADULT;

EID: 84951310023     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0000000000000574     Document Type: Article

References (39)

1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359-E386.
2. Matsuno S, Egawa S, Fukuyama S, et al. Pancreatic Cancer Registry in Japan: 20 years of experience. Pancreas. 2004;28:219-230.
3. Vincent A, Herman J, Schulick R, et al. Pancreatic cancer. Lancet. 2011;378:607-620.
4. Bergmann F, Aulmann S, Wente MN, et al. Molecular characterisation of pancreatic ductal adenocarcinoma in patients under 40. J Clin Pathol. 2006;59:580-584.
5. Yachida S, Iacobuzio-Donahue CA. Evolution and dynamics of pancreatic cancer progression. Oncogene. 2013;32:5253-5260.
6. Yachida S, Jones S, Bozic I, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 2010;467:1114-1117.
7. Goggins M, Schutte M, Lu J, et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res. 1996;56:5360-5364.
8. Jones S, Hruban RH, Kamiyama M, et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science. 2009;324:217.
9. Roberts NJ, Jiao Y, Yu J, et al. ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov. 2012;2:41-46.
10. Humphris JL, Johns AL, Simpson SH, et al. Clinical and pathologic features of familial pancreatic cancer. Cancer. 2014;120:3669-3675.
11. Klein AP. Identifying people at a high risk of developing pancreatic cancer. Nat Rev Cancer. 2013;13:66-74.
12. Duffy A, Capanu M, Allen P, et al. Pancreatic adenocarcinoma in a young patient population-12-year experience at Memorial Sloan Kettering Cancer Center. J Surg Oncol. 2009;100:8-12.
13. He J, Edil BH, Cameron JL, et al. Young patients undergoing resection of pancreatic cancer fare better than their older counterparts. J Gastrointest Surg. 2013;17:339-344.
14. Lüttges J, Stigge C, Pacena M, et al. Rare ductal adenocarcinoma of the pancreas in patients younger than age 40 years. Cancer. 2004;100: 173-182.
15. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25:1754-1760.
16. McKenna A, Hanna M, Banks E, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20:1297-1303.
17. 1000 Genomes Project ConsortiumAbecasis GR, Altshuler D, et al. A map of human genome variation from population-scale sequencing. Nature. 2010;467:1061-1073.
18. 1000 Genomes Project ConsortiumAbecasis GR, Auton A, et al. An integrated map of genetic variation from 1,092 human genomes. Nature. 2012;491:56-65.
19. Sherry ST, Ward MH, Kholodov M, et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 2001;29:308-311.
20. Thompson BA, Spurdle AB, Plazzer JP, et al. Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database. Nat Genet. 2014;46:107-115.
21. Vallée MP, Francy TC, Judkins MK, et al. Classification of missense substitutions in the BRCA genes: a database dedicated to Ex-UVs. Hum Mutat. 2012;33:22-28.
22. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc. 2009;4:1073-1081.
23. Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. Nat Methods. 2010;7:248-249.
24. Wei Ow SG, Tan KT, Yang H, et al. Using next-generation sequencing (NGS) to identify causative mutations in Asian cancer (CA) patients with suspected Lynch syndrome. J ClinOncol. 2014;32:5s (Suppl; abstr 1540).
25. Faustino NA, Cooper TA. Pre-mRNA splicing and human disease. Genes Dev. 2003;17:419-437.
26. Edelbrock MA, Kaliyaperumal S, Williams KJ. Structural, molecular and cellular functions of MSH2 and MSH6 during DNA mismatch repair, damage signaling and other noncanonical activities. Mutat Res. 2013; 743-744:53-66.
27. Laguri C, Duband-Goulet I, Friedrich N, et al. Human mismatch repair protein MSH6 contains a PWWP domain that targets double stranded DNA. Biochemistry. 2008;47:6199-6207.
28. Lamers MH, Perrakis A, Enzlin JH, et al. The crystal structure of DNA mismatch repair protein MutS binding to a G x T mismatch. Nature. 2000; 407:711-717.
29. Alani E, Sokolsky T, Studamire B, et al. Genetic and biochemical analysis of Msh2p-Msh6p: role of ATP hydrolysis and Msh2p-Msh6p subunit interactions in mismatch base pair recognition. Mol Cell Biol. 1997;17: 2436-2447.
30. Oliveira C, Pinheiro H, Figueiredo J, et al. Familial gastric cancer: genetic susceptibility, pathology, and implications for management. Lancet Oncol. 2015;16:e60-e70.
31. Yabuta T, Shinmura K, Tani M, et al. E-cadherin gene variants in gastric cancer families whose probands are diagnosed with diffuse gastric cancer. Int J Cancer. 2002;101:434-441.
32. Suriano G, Oliveira MJ, Huntsman D, et al. E-cadherin germline missense mutations and cell phenotype: evidence for the independence of cell invasion on the motile capabilities of the cells. Hum Mol Genet. 2003;12:3007-3016.
33. Curtis MW, Ly QP, Wheelock MJ, et al. Evidence that the V832M E-cadherin germ-line missense mutation does not influence the affinity of alpha-catenin for the cadherin/catenin complex. Cell Commun Adhes. 2007;14:45-55.
34. Gilabert M, Turrini O, Niccoli P, et al. Solid pancreatic tumors in patients younger than 40 years old-experience of a French comprehensive cancer center. Pancreas. 2015;44:345-346.
35. Hassan MM, Bondy ML, Wolff RA, et al. Risk factors for pancreatic cancer: case-control study. Am J Gastroenterol. 2007;102:2696-2707.
36. Morizane C, Okusaka T, Mizusawa J, et al. Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805). Cancer Sci. 2013; 104:1211-1216.
37. Grant RC, Selander I, Connor AA, et al. Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer. Gastroenterology. 2015;148:556-564.
38. McFaul CD, Greenhalf W, Earl J, et al. Anticipation in familial pancreatic cancer. Gut. 2006;55:252-258.
39. Piciucchi M, Capurso G, Valente R, et al. Early onset pancreatic cancer: risk factors, presentation and outcome. Pancreatology. 2015;15: 151-155.